-- 4DMedical (ASX:4DX) secured a one-year contract with GlaxoSmithKline, in collaboration with imaging data platform Flywheel Exchange, to provide its quantitative lung imaging analytics from May to support pulmonary drug development and clinical research, according to a Monday filing with the Australian bourse.
Additionally, the company's CT:VQ imaging technology obtained UK Conformity Assessed certification, allowing for the commercial deployment across both public and private healthcare providers within the UK, the filing said.
The company will also be included in the S&P/ASX 200 Index, effective before the open of trading on Monday, per the filing.
4DMedical's shares rose around 1% in morning trade Monday.